Aminoglycoside antibiotics are widely used for the treatment of serious gram-negative bacterial infections. Their utility is being threatened, however, by the appearance of resistant bacteria which, in the majority of clinical situations, possess enzymes capable of inactivating one or more aminoglycosides (3, 5) . Although the inactivating enzymes vary considerably in their substrate specificities, known modifications are restricted to acetylation of amino groups and adenylylation or phosphorylation of hydroxyl groups (3, 5, 7) .
UK-18,892 ( Fig. 1 ) is a new semisynthetic aminoglycoside derived from kanamycin A, which is active in vitro against both aminoglycoside-susceptible and aminoglycoside-resistant bacteria (11) . In the present study we have examined the ability of enzymes in cell-free extracts of aminoglycoside-resistant bacteria to modify UK-18,892 and have compared the extent of modification with that obtained with other aminoglycosides. In addition, we report the efficacy of UK-18,892 against experimental infections in mice caused by bacteria possessing aminoglycoside-inactivating enzymes.
MATERIALS AND METHODS
Bacterial isolates. The sources of bacteria and the types of aminoglycoside-inactivating enzymes present in each strain are shown in Table 1 . The enzymes present in those bacteria designated clinical isolates, together with Pseudomonas HK232 and Proteus HK 238, were deduced from the pattern of resistance exhibited by each isolate against a panel of nine aminoglycosides, as described by Price et al. (10) . The inactivating enzymes present in the remaining aminoglycoside-resistant bacteria were identified by the workers who supplied these isolates ( Cell-free enzyme extracts. Cell-free bacterial enzyme extracts were prepared by methods similar to published procedures (2, 8) .
Bacteria were grown for 18 h at 370C in brain heart infusion broth (Difco) containing 10 ,ug of an appropriate aminoglycoside per ml. i.e., one to which the isolate was resistant. This "starter broth" (5 ml) was inoculated into 500 ml of antibiotic-free brain heart infusion and grown at 370C, with aeration, until the culture was in the late-log phase. The 
RESULTS
Enzymatic modification of aminoglycosides. The relative degrees of modification of UK-18,892, gentamicin, and kanamycin B by cell-free enzyme preparations of APH(3')-I, AAD(2"), AAC(3), AAC(2'), AAC(6'), and AAD(4'), together with the MIC of the three aminoglycosides against the bacteria from which the enzymes were isolated, are shown in Table  2 .
The degree of enzymatic modification was determined at pH 6, 7, and 8 because different enzymes and aminoglycosides have been shown to have varying pH optima in such systems (1, 4, 8) . Accordingly, the highest radioactivity value obtained was used in calculating the extent of modification. For each enzyme, an arbitrary value of 100 was assigned to the aminoglycoside with the highest associated radioactivity, and the extent of modification of the other two was expressed relative to this.
UK-18,892 was a substrate for only AAC(6') and AAD(4'), and the organisms containing these enzymes (E. coli NR79/W677 and S. epidermidis 109) were resistant to this antibiotic. The remaining four aminoglycoside-resistant bacteria were susceptible to UK-18,892.
Kanamycin B was a substrate for all six enzymes examined, whereas gentamicin was not modified significantly by APH(3')-I or AAD(4'). The bacteria containing these latter two enzymes, E. coli JR35/25 and S. epidermidis 109, were characteristically susceptible to gentamicin, whereas the other organisms examined were resistant to this aminoglycoside. Kanamycin B was inactive against four of the organisms tested (E. coli RIP55, E. coli JR35/25, S. epidernidis 109, and Providencia 164), but had weak activity against E. coli NR79/W677 and was typically active against E. coli RIP135.
Lethal infections in mice. No examples of AAC(6') were identified, and only one 4'-adenylylating [AAD(4')] enzyme was found. UK-18,892 inhibited 93% of these isolates at 12.5 ,tg/ml, and more than half of the remaining UK-18,892-resistant isolates showed high-level resistance to all other aminoglycosides studied, possibly indicating resistance by mechanisms other than enzymatic inactivation. We concluded that UK-18,892 was not inactivated by the most commonly encountered inactiving enzymes found in aminoglycoside-resistant bacteria isolated in the clinics.
In the present study we have attempted to confirm this conclusion by using cell-free extracts of bacteria containing known inactivating enzymes. Gentamicin and kanamycin B were chosen for comparison, because together they possess most of the amino and hydroxyl groups of aminoglycosides which are susceptible to enzymatic modification. UK-18,892 is not a substrate for APH(3')-I, AAD(2"), AAC(3), or AAC(2') in cell-free enzyme preparations obtained from aminoglycoside-resistant bacteria ( 892 does not possess a 2'-amino group. However, because UK-18,892 possesses 3'-hydroxyl, 2"-hydroxyl, and 3-amino groups, it would appear that substitution at the 1-amino group of kanamycin A by a 4-amino-2-hydroxybutyl moiety prevents inactivation by APH(3')-I, AAD(2"), and AAC(3). Both AAC(6') and AAD(4') enzymes inactivate UK-18,892. Similar findings have been reported for amikacin (6, 8, 12) .
Although kanamycin B is a substrate for all six enzymes examined, it is not completely inactivated by bacteria containing AAC(3) and AAC(6'), as evidenced by its MIC against E. coli NR79/W677 and E. coli RUP135. It is possible that the rate of modification of kanamycin B by intact bacteria is too slow to prevent its antibacterial action. Because gentamicin does not possess 3'-or 4'-hydroxyl groups, it is not modified by APH(3')-I or AAD(4') and is therefore active against organisms containing these enzymes. It is, however, a substrate for AAD(2"), AAC(2'), and AAC(6'), although E. coli NR79/W677, which possesses AAC(6'), is susceptible to gentamicin. This is because two of the three components of commercial gentamicin (gentamicin CIA and C2) are still antibacterially active after modification by AAC(6') (1). The third active component, gentamicin Cl, is not a substrate for AAC(6') (1).
In mice, UK-18,892 is effective against infections caused by bacteria possessing APH(3')-I, AAD(2"), AAC(3), and AAC(2') enzymes, including three isolates possessing more than one enzyme. The degree of protection is consistent with the MIC of UK-18,892 against the infecting organism. Although we have not evaluated UK-18,892 against infections caused by bacteria possessing either AAC(6') or AAD(4'), it is unlikely that it would afford useful protection against such organisms in the absence of adequate in vitro activity.
The in vivo protection afforded by gentamicin and kanamycin B is also readily correlated with their activity in vitro. Gentamicin is considerably less effective against organisms possessing AAD(2") and AAC(3) enzymes than against the same species of aminoglycoside-susceptible bacteria. Similarly, kanamycin B does not afford useful protection against organisms possessing APH(3')-I, AAD(2"), or AAC(2').
In conclusion, the assumption made earlier (11; unpublished data) that the potent in vitro activity of UK-18,892 against aminoglycosideresistant bacteria is due to its resistance to modification by most of the known aminoglycosideinactivating enzymes has been verified. In addition, it is demonstrated that UK-18,892 protects against lethal infections in mice caused by these organisms.
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